Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 2.0% in the third quarter, HoldingsChannel.com reports. The firm owned 114,834 shares of the company’s stock after selling 2,361 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in IDEXX Laboratories were worth $59,966,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the business. Aries Wealth Management acquired a new stake in IDEXX Laboratories in the third quarter valued at $1,670,000. Live Oak Investment Partners lifted its holdings in IDEXX Laboratories by 1.5% during the 3rd quarter. Live Oak Investment Partners now owns 2,516 shares of the company’s stock worth $1,314,000 after buying an additional 38 shares during the last quarter. Signaturefd LLC lifted its holdings in IDEXX Laboratories by 21.4% during the 3rd quarter. Signaturefd LLC now owns 1,964 shares of the company’s stock worth $1,026,000 after buying an additional 346 shares during the last quarter. Citizens Financial Group Inc. RI boosted its position in shares of IDEXX Laboratories by 51.1% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 3,400 shares of the company’s stock worth $1,776,000 after acquiring an additional 1,150 shares in the last quarter. Finally, One Wealth Capital Management LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $699,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.
Insider Buying and Selling at IDEXX Laboratories
In other news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.79% of the company’s stock.
Wall Street Analysts Forecast Growth
IDXX has been the topic of a number of recent analyst reports. KeyCorp began coverage on IDEXX Laboratories in a report on Monday, October 12th. They issued a “sector weight” rating on the stock. UBS Group raised their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Barclays decreased their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Citigroup upped their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Finally, The Goldman Sachs Group began coverage on shares of IDEXX Laboratories in a research note on Friday, October 16th. They issued a “buy” rating and a $740.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $744.09.
Get Our Latest Stock Analysis on IDEXX Laboratories
IDEXX Laboratories Stock Performance
NASDAQ:IDXX opened at $560.38 on Monday. The stock’s 50 day moving average price is $532.69 and its 200 day moving average price is $551.46. The company has a market capitalization of $44.15 billion, a PE ratio of 39.41 and a beta of 1.55. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same quarter in the previous year, the company posted $3.50 earnings per share. The firm’s revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.
About IDEXX Laboratories
IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.
IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.
Featured Articles
- Five stocks we like better than IDEXX Laboratories
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
- Can Planet Fitness Get Its Growth Back in Shape?
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
